Last updated on July 2019

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)


Brief description of study

The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.

Detailed Study Description

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), 2) time from first day of hematopoietic cell infusion to randomization (30-60 days vs. 61-90 days) and 3) presence vs absence of or unknown minimal residual disease (MRD) from the most recent pre-registration bone marrow (BM) aspirate.

Clinical Study Identifier: NCT02997202

Find a site near you

Start Over

Mayo Clinic

Phoenix, AZ United States
  Connect »

Virginia G Piper Cancer Center

Scottsdale, AZ United States
  Connect »

Stanford University

Stanford, CA United States
  Connect »

University of Florida

Gainesville, FL United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Northside

Atlanta, GA United States
  Connect »

Augusta University

Augusta, GA United States
  Connect »

Johns Hopkins Hospital

Baltimore, MD United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

University of Massachusetts

Worcester, MA United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Karmanos Cancer Center

Detroit, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Memorial Sloan Kettering

New York, NY United States
  Connect »

Weill Cornell Medical Center

New York, NY United States
  Connect »

University of North Carolina

Chapel Hill, NC United States
  Connect »

Wake Forest Baptist Health

Winston-Salem, NC United States
  Connect »

Oncology Hematology Care, Inc

Cincinnati, OH United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Ohio State University, The

Columbus, OH United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Texas Transplant Institute

San Antonio, TX United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Intermountain BMT

Salt Lake City, UT United States
  Connect »

University of Virginia

Charlottesville, VA United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Site AU61001

Liverpool, Australia
  Connect »

Site AU61002

Melbourne, Australia
  Connect »

Site AU61004

Westmead, Australia
  Connect »

Site BE32003

Bruxelles, Belgium
  Connect »

Site BE32002

Edegem, Belgium
  Connect »

Site CA15003

Montreal, Canada
  Connect »

Site CA15002

Winnipeg, Canada
  Connect »

Site DK45001

Copenhagen, Denmark
  Connect »

Site FR33012

Besancon, France
  Connect »

Site FR33009

Marseille, France
  Connect »

Site FR33006

Montpellier Cedex 5, France
  Connect »

Site FR33002

Toulouse Cedex 9, France
  Connect »

Site FR33010

Vandoeuvre-Les-Nancy, France
  Connect »

Site DE49002

Düsseldorf, Germany
  Connect »

Site DE49003

Halle (Saale), Germany
  Connect »

Site DE49005

Hamburg, Germany
  Connect »

Site DE49004

Münster, Germany
  Connect »

Site DE49009

Stuttgart, Germany
  Connect »

Site GR30001

Thessaloniki, Greece
  Connect »

Site JP81012

Nishinomiya, Japan
  Connect »

Site JP81007

Yokohama, Japan
  Connect »

Site JP81008

Shimotsuke, Japan
  Connect »

Site JP81013

Bunkyo-ku, Japan
  Connect »

Site JP81016

Minato-ku, Japan
  Connect »

Site JP81020

Shinjuku-ku, Japan
  Connect »

Site JP81019

Kagoshima, Japan
  Connect »

Site KR82001

Seoul, Korea, Republic of
  Connect »

Site KR82002

Seoul, Korea, Republic of
  Connect »

Site KR82003

Seoul, Korea, Republic of
  Connect »

Site KR82004

Seoul, Korea, Republic of
  Connect »

Site KR82005

Seoul, Korea, Republic of
  Connect »

Site NZ64003

Dunedin, New Zealand
  Connect »

Site NZ64001

Grafton, New Zealand
  Connect »

Site PL48004

Warszawa, Poland
  Connect »

Site ES34003

Barcelona, Spain
  Connect »

Site ES34005

Barcelona, Spain
  Connect »

Site ES34006

Salamanca, Spain
  Connect »

Site ES34007

Santander, Spain
  Connect »

Site ES34002

Valencia, Spain
  Connect »

Site TW88601

Kaohsiung, Taiwan
  Connect »

Site TW88603

Taichung, Taiwan
  Connect »

Site TW88605

Taoyuan, Taiwan
  Connect »

Site GB44010

Birmingham, United Kingdom
  Connect »

Site GB44003

Bristol, United Kingdom
  Connect »

Site GB44009

Glasgow, United Kingdom
  Connect »

Site GB44004

London, United Kingdom
  Connect »

Site GB44002

Manchester, United Kingdom
  Connect »

Site GB44005

Nottingham, United Kingdom
  Connect »

Site GB44001

Sutton, United Kingdom
  Connect »

Site DE49002

Düsseldorf, Germany
  Connect »

Site DE49004

Münster, Germany
  Connect »

Site DE49002

Düsseldorf, Germany
  Connect »

Site DE49004

Münster, Germany
  Connect »

Site DE49002

Düsseldorf, Germany
  Connect »

Site DE49004

Münster, Germany
  Connect »